Xenograft Model Development Services
Alfa Cytology specializes in providing state-of-the-art xenograft model development services designed to enhance the preclinical evaluation of cancer therapies. Our primary objective is to provide highly predictive in vivo models that mimic human tumor biology, facilitating the assessment of therapeutic efficacy and safety.
Introduction of Xenograft Model
Xenotransplantation is the transplantation of cells or tissues between different species, which is commonly used to test the efficacy of new cancer treatments in preclinical studies of cancer therapies. Xenograft models involve transplanting human tumor cells into immunocompromised mice to create a living system that closely replicates human cancer. These models help researchers gain insight into tumor growth, metastasis, and therapy response.
Fig.1 Xenograft model. Cell line-derived (A) or patient-derived (B) cells can be transplanted into immunocompromised mice to study tumor biology and behavior. (Kohnken, R., et al., 2017)
Depending on the purpose of the study, xenograft models can be categorized into several types, including cell line-derived xenografts (CDX) and patient-derived xenografts (PDX), among others. Significant progress has been made in the development of current xenograft models, with a focus on improving the fidelity and applicability of these models.
Human Cell Lines for Utilized Xenograft Models
Human cell lines are derived from various cancer types and provide a controlled and reproducible system for in vivo studies. Here are some examples of human cell lines commonly used in the development of xenograft models.
Tumor Origin |
Common Human Cell Lines |
Advantages & Applications |
Lung |
A549 |
Well-characterized, consistent growth, drug responsiveness. |
Breast |
MCF-7 |
Hormone receptor studies, endocrine treatment testing, hormone resistance. |
Prostate |
PC-3/ DU145 |
Androgen-independent, robust xenografts, advanced prostate cancer. |
Colorectum |
HT-29/ HCT116 |
Androgen-independent, robust xenografts, advanced prostate cancer. |
Glioblastoma |
U87-MG |
Orthotopic models, brain tumor environment, invasion studies. |
Ovarian |
SKOV-3 |
Reliable xenografts, chemotherapy efficacy, targeted therapies. |
Our Services
With a well-established technology platform of the tumor microenvironment center, Alfa Cytology provides our clients with one-stop solutions for xenograft model development. Our team of expert scientists can tailor the perfect preclinical efficacy testing strategy for your specific research needs.
Xenograft Models Available
Alfa Cytology is committed to developing the most advanced and comprehensive xenograft models for preclinical research, each tailored to specific research needs. These models include:
Xenograft Model Construction Process
Building xenograft models is a complex and detailed process that requires careful planning, precise execution and rigorous monitoring. Alfa Cytology's model-building service follows a structured methodology that ensures reliable and reproducible results.
Model Selection
Conduct initial project discussions and then select the appropriate type of xenograft model (CDX, PDX, in situ, etc.) based on the research objectives.
Cell Preparation
Perform genetic and phenotypic characterization of the selected cell line to ensure identity and purity. Cells are then expanded to obtain sufficient numbers and viability.
Tumor Cell Implantation
Tumor cells are implanted (subcutaneously or in situ) into immunocompromised mice suitable for the specific tumor type under study.
Verification of Model Construction
Verify successful tumor engraftment through initial monitoring using imaging techniques and regular assessments of tumor growth and animal health.
Alfa Cytology provides comprehensive solutions to address key challenges encountered in the field of cancer therapy development. With extensive experience in a wide range of cancer models and expertise in tumors and microenvironments, we are committed to providing our clients with the most accurate in vivo cancer models to meet the precise needs. For inquiries or to learn more about how we can support your cancer research program, please contact us.
Reference
- Kohnken, R., et al.; (2017). Overview of the use of murine models in leukemia and lymphoma research. Frontiers in oncology, 7, 22.
For research use only.
Related Services